The New Generation of Liquid Intravenous Immunoglobulin Formulations in Patient Care: A Comparison of Intravenous Immunoglobulins

References

• . Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722–728
   PubMed Web of Science ®Google Scholar
• . Janeway CA, Apt L, Gitlin D. Agammaglobulinemia. Trans Assoc Am Physicians. 1953;66:200–202
   PubMedGoogle Scholar
• . Gitlin D, Janeway CA. Agammaglobulinemia: congenital, acquired and transient forms. Prog Hematol. 1956;1:318–329
   PubMedGoogle Scholar
• . Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112(1):1–7
   PubMed Web of Science ®Google Scholar
• . Cunningham-Rundles C, Siegal FP, Smithwick EM, . Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med. 1984;101(4):435–439
   PubMed Web of Science ®Google Scholar
• . Orange JS, Hossny EM, Weiler CR, ; Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immune globulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006; 117;(4 suppl 1):S525–S553
   PubMed Web of Science ®Google Scholar
• . Kuitwaard K, de Gelder J, Tio-Gillen AP, . Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol. 2009;66(5):597–603
   PubMed Web of Science ®Google Scholar
• . Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142(1):1–11
   PubMed Web of Science ®Google Scholar
• . Bonilla FA, Bernstein IL, Khan DA, ; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005; 94:S1–S63
   PubMed Web of Science ®Google Scholar
• . Shehata N, Palda V, Bowen T, . The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfusion Med Rev. 2010;24( suppl 1):S28–S50
   PubMed Web of Science ®Google Scholar
• . Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant. 2003;3:653–664
   PubMed Web of Science ®Google Scholar
• . Yamani MH, Avery R, Mawhorter S, . Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes. Transplant Infect Dis. 2001;3( suppl 2):40–43
   PubMedGoogle Scholar
• . Stucki M, Boschetti N, Schaefer W, . Investigations of prion and virus safety of a new liquid IVIG product. Biologicals. 2008;36(4):239–247
   PubMed Web of Science ®Google Scholar
• . Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 2010;98(11):12–28
   Google Scholar
• . Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol. 2006;6(4):595–599
   Google Scholar
• . Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm. 2005;62( suppl 3):S5–S11
   PubMed Web of Science ®Google Scholar
• . Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol. 2007;87(3):206–218
   PubMed Web of Science ®Google Scholar
• . Siegel J. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy. 2005;25(11 pt 2):78S–84S
   PubMed Web of Science ®Google Scholar
• . Gammagard SD [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2008
   Google Scholar
• . Carimune NF [package insert]. King of Prussia, PA: CSL Behring LLC; 2005
   Google Scholar
• . Gaines A, Varricchio F, Kapit R, . Renal insufficiency and failure associated with globulin intravenous therapy. Morb Mortal Wkly Rep. 1999;48:518–521
   PubMedGoogle Scholar
• . Flebogamma 5% DIF [package insert]. Los Angeles, CA: Grifols Biologicals, Inc; 2006
   Google Scholar
• . Octagam [package insert]. Centreville, VA: Octapharma USA, Inc; 2006
   Google Scholar
• . Gammaplex [package insert]. Elstree, UK: Bio Products Laboratory; 2009
   Google Scholar
• . Gamunex [package insert]. Research Triangle Park, NC: Talecris. Biotherapeutics, Inc; 2008
   Google Scholar
• . Privigen [package insert]. King of Prussia, PA: CSL Behring LLC; 2010
   Google Scholar
• . Gammagard Liquid [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2005
   Google Scholar
• . Kallenberg CGM, Laseur M. Cost considerations in choosing an intravenous immunoglobulin preparation. EJHP Practice. 2007;2:66–68
   Google Scholar
• . Sorensen R. Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin. J Manag Care Pharm. 2007;13(3):278–283
   Google Scholar
• . Berger M; the Flebogamma® 5% DIF Investigators. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma® 5% DIF, the next generation of Flebogamma®. J Clin Immunol. 2007; 27(6):628–633
   PubMed Web of Science ®Google Scholar
• . Cramer M, Frei R, Sebald A, . Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen©) stabilized with L-proline. Vox Sang. 2009;96(3):219–225
   Google Scholar
• . Kallenberg CG. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency. Clin Exp Immunol. 2007;150(3):437–441
   Google Scholar
• . Ballow M, Berger M, Bonilla FA, . Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang. 2003;84(3):202–210
   PubMed Web of Science ®Google Scholar
• . Roifman CM, Schroeder H, Berger M, . Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol. 2003;3(9):1325–1333
   Google Scholar
• . Church JA, Leibl H, Stein MR, ; US-PID-IGIV 10%-Study Group10. Effcacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006; 26(4):388–395
   PubMed Web of Science ®Google Scholar
• . Björkander J, Nikoskelainen J, Leibl H, . Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang. 2006;90(4):286–293
   PubMed Web of Science ®Google Scholar
• . Stein MR, Nelson RP, Church JA, ; for the IgPro10 in PID Study Group. Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. Clin Immunol. 2009; 29(1):137–144
   Google Scholar
• . Siegel J. Safety considerations in IGIV utilization. Int Immunopharmacol. 2006;6(4):523–527
   Google Scholar
• . Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia: detection of IgE antibodies to IgA. N Engl J Med. 1986;314(9):560–564
   PubMed Web of Science ®Google Scholar
• . Manlhiot C, Tyrrell PN, Liang L, . Safety of intravenous immuno-globulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics. 2008;121(3):e626–e630
   Google Scholar
• . Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet. 1992;339(8794):682–684
   Google Scholar
• . Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology. 2003;60(11):1822–1824
   PubMed Web of Science ®Google Scholar
• . Bolli R, Woodtli K, Bartschi M, . L-proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals. 2010;38(1):150–157
   PubMed Web of Science ®Google Scholar
• . Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin N Am. 2008;28:779–802
   PubMed Web of Science ®Google Scholar
• . Stangel M, Hartung HP, Marx P, Gold R. Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol. 1997;20:385–393
   Google Scholar
• . Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol. 2003;50(3):172–175
   PubMed Web of Science ®Google Scholar
• . Berger M, Cunningham-Rundles C, Bonilla FA, . Carimune NF is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. J Clin Immunol. 2007;27(5):503–509
   Google Scholar
• . Brennan VM, Salomé-Bentley NJ, Chapel HM; Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol. 2003;133(2):247–251
   Web of Science ®Google Scholar
• . Ameratunga R, Sinclair J, Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol. 2004;136(1):111–113
   PubMed Web of Science ®Google Scholar
• . Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29(3):173–184
   PubMed Web of Science ®Google Scholar
• . Hamrock DJ. Adverse events associated with intravenous immuno-globulin therapy. Int Immunopharmacol. 2006;6(4):535–542
   PubMed Web of Science ®Google Scholar
• . Gelfand EW, Hanna K; and the IGIV-C Increased Maximum Infusion Rate Study Group. Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients. J Clin Immunol. 2006; 26(3):284–290
   Google Scholar
• . Sleasman JW, Duff CM, Dunaway T, . Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen®, at different infusion rates. J Clin Immunol. 2010;30(3):442–448
   PubMed Web of Science ®Google Scholar
• . Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfusion Med Rev. 2003;17(4):241–251
   Web of Science ®Google Scholar
• . Chapman SA, Gilkerson KL, Davin TD, Pritzker MR. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother. 2004;38(12):2059–2067
   PubMed Web of Science ®Google Scholar
• . Ahsan N. Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy. J Nephrol. 1998;11(3):157–161
   PubMed Web of Science ®Google Scholar
• . Horn J, Thon V, Bartonkova D, . Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol. 2007;122(2):156–162
   PubMed Web of Science ®Google Scholar
• . Björkander J, Hammarstrom L, Smith CI, . Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol. 1987;7(1):8–15
   Google Scholar
• . Koskinen S, Tolo H, Hirvonen M, Koistinen J. Long-term follow-up of anti-IgA antibodies in healthy IgA-deficient adults. J Clin Immunol. 1995;15(4):194–198
   Google Scholar
• . Aghamohammadi A, Cheraghi T, Gharagozlou M, . IgA deficiency: correlation between clinical and immunological phenotypes. J Clin Immunol. 2009;29(1):130–136
   PubMed Web of Science ®Google Scholar
• . Eijkhout HW, van den Broek PJ, van der Meer JWM. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med. 2003;61(6):213–217
   PubMed Web of Science ®Google Scholar
• . Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement by slow subcutaneous infusion. Ann Intern Med. 1980;98(1):55–56
   Google Scholar
• . Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121(4):259–262
   PubMed Web of Science ®Google Scholar
• . Iagaru N, Cinteza E, Cochino AV. Adverse reactions to intravenous immunoglobulin therapy. Medica. 2007;2:294–299
   Google Scholar
• . Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica. 1993;78(6 suppl 2):35–40
   Google Scholar
• . Daw Z, Padmore R, Neurath D, . Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion. 2008;48(8):1598–1601
   PubMed Web of Science ®Google Scholar
• . Marie I, Maurey G, Hervé F, . Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. 2006;155(4):714–721
   PubMed Web of Science ®Google Scholar
• . Paran D, Herishanu Y, Elkayam O, . Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis. 2005;16(5):313–318
   PubMed Web of Science ®Google Scholar
• . Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44(2):223–226
   PubMed Web of Science ®Google Scholar
• . Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol. 2000;65(1):30–34
   PubMed Web of Science ®Google Scholar
• . Cailleux N, Levesque H, Bastit D, . A rare cause of intra-alveolar hemorrhage: a transfusion-related incident with leukoagglutination due to antigranulocyte antibodies (Trali syndrome) [in French]. Rev Med Interne. 1998;19(6):434–437
   PubMed Web of Science ®Google Scholar
• . Gajic O, Moore SB. Transfusion-related acute lung injury. Mayo Clin Proc. 2005;80(6):766–770
   Google Scholar
• . Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion. 2001;41(2):264–268
   Google Scholar
• . Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin N Am. 2008;28(2):413–437
   PubMed Web of Science ®Google Scholar
• . Asia Pacific Immunoglobulins in Immunology Expert Group. Consensus recommendations for the use of immunoglobulin replacement therapy in immune deficiency. November 2008
   Google Scholar
• . Desai SH, Chouksey A, Poll J, Berger M. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously. J Allergy Clin Immunol. 2009;124(4):854–856
   PubMed Web of Science ®Google Scholar
• . Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am. 2008;28(4):737–764
   PubMed Web of Science ®Google Scholar
• . Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;1(8541):1075–1077
   PubMed Web of Science ®Google Scholar
• . Gelfand EW, Reid B, Roifman CM. Intravenous immune serum globulin replacement in hypogammaglobulinemia. A comparison of high-versus low-dose therapy. Monogr Allergy. 1988;23:177–186
   Google Scholar
• . Roifman CM, Gelfand EW. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia. Pediatr Infect Dis J. 1988;7(5 suppl):S92–S96
   Google Scholar
• . Eijkhout HW, van Der Meer JW, Kallenberg CG, ; Inter-University Working Party for the Study of Immune Deficiencies. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001; 135(3):165–174
   PubMed Web of Science ®Google Scholar
• . Roifman CM, Berger M, Notarangelo LD. Management of primary antibody deficiency with replacement therapy: summary of guidelines. Immunol Allergy Clin North Am. 2008;28(4):875–876
   PubMed Web of Science ®Google Scholar